Interfering nanoparticles for silencing microRNAs.

Methods in Enzymology
Huricha Baigude, Tariq M Rana

Abstract

MicroRNAs (miRNAs) are single-stranded noncoding RNAs ∼21-nucleotide (nt) in length and regulate gene expression at the posttranscriptional level. miRNAs are involved in almost every area of biology, including developmental processes, disease pathogenesis, and host-pathogen interactions. Dysregulation of miRNAs in various disease states makes them potential targets for therapeutic intervention. Specific miRNAs can be silenced by anti-microRNAs (anti-miRs) that are chemically modified antisense oligonucleotides complementary to mature miRNA sequences. In vivo delivery of anti-miRs is the main barrier in achieving efficient silencing of target miRNAs. A new systemic delivery agent, interfering nanoparticles (iNOPs), was designed and prepared from lipid-functionalized poly-L-lysine dendrimer. iNOPs can efficiently deliver small RNAs, including short interfering RNAs, miRNA mimics, and anti-miRs. Systemic delivery of a chemically stabilized anti-miR-122 by iNOPs effectively silences miR-122 in mouse liver. Intravenous administration of 2 mg/kg anti-miR-122 complexed with iNOP-7 results in 83% specific silencing of target miRNA. The specific silencing of miR-122 by iNOP-7 is long lasting and does not induce an immune response.

Citations

May 9, 2014·BioMed Research International·Can-Jie GuoXiong Ma
Nov 24, 2012·Drug Delivery·Dimitry A ChistiakovAlexander N Orekhov
Dec 2, 2014·Expert Opinion on Therapeutic Targets·Dian-Na GuLing Tian
Sep 25, 2014·Advanced Drug Delivery Reviews·Deepak ChitkaraRam I Mahato
Sep 3, 2013·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Rammohan Devulapally, Ramasamy Paulmurugan
Oct 30, 2013·Critical Reviews in Biochemistry and Molecular Biology·Veena S PatilTariq M Rana
Sep 5, 2019·Mini Reviews in Medicinal Chemistry·Miao LiJun Dou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.